Prolia (Denosumab) vs Evenity (Romosozumab): Switching Between Them

How These Two Drugs Work Differently

Denosumab and romosozumab occupy opposite ends of the osteoporosis treatment spectrum, and understanding that difference is the entire basis for switching decisions.

Denosumab is a monoclonal antibody that binds RANK ligand, the signaling molecule osteoclasts need to mature and resorb bone. By blocking RANKL, denosumab suppresses bone turnover. Markers of bone resorption (serum CTX) drop within days of injection and stay suppressed for roughly 6 months, which is why the drug is dosed twice yearly (FDA label, 2010). The FREEDOM trial (N=7,868) demonstrated a 68% reduction in vertebral fractures over 3 years, with continued benefit through 10 years in the extension study [2].

Romosozumab works differently. It is a monoclonal antibody against sclerostin, a protein secreted by osteocytes that normally puts the brakes on bone formation. Blocking sclerostin does two things simultaneously: it stimulates osteoblast activity (bone building) and reduces osteoclast activity (bone breakdown). This dual effect produces rapid gains in bone mineral density (BMD) that no antiresorptive agent can match. In the ARCH trial (N=4,093), 12 months of romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone at 24 months [1].

The catch: romosozumab's bone-forming effect fades. Bone formation markers peak around month 6, then decline toward baseline by month 12. That waning effect is why the drug is limited to 12 monthly doses and why a follow-on antiresorptive is not optional. It is required.

Why Sequencing Matters More Than Choosing One Over the Other

For most patients with high fracture risk, this is not a question of picking denosumab or romosozumab. It is a question of order.

The Endocrine Society's 2020 guidelines recommend that patients at very high fracture risk (prior vertebral fracture, T-score below -3.0, or high FRAX probability) start with an anabolic agent before transitioning to an antiresorptive (Shoback et al., JCEM 2020). The American Association of Clinical Endocrinology (AACE) 2020 guidelines echo this recommendation, defining "very high risk" and "extremely high risk" tiers where romosozumab is the preferred first step (Camacho et al., Endocr Pract 2020).

The clinical logic is straightforward. Anabolic agents build bone mass quickly. Antiresorptive agents hold onto those gains. Starting with the anabolic phase and consolidating with antiresorptive therapy produces greater cumulative BMD improvement than the reverse order.

Data from the FRAME extension and transition studies illustrate this clearly. Patients who received romosozumab for 12 months then transitioned to denosumab gained a total of 11.2% lumbar spine BMD at 24 months. Those who went from placebo to denosumab gained 7.3% (Bone et al., Lancet Diabetes Endocrinol 2018). The romosozumab-first group started from a higher plateau.

Switching from Romosozumab to Denosumab: The Well-Studied Path

This is the direction supported by the most evidence and the one most clinicians follow in practice.

After completing 12 monthly injections of romosozumab (210 mg subcutaneous), the patient transitions directly to denosumab 60 mg subcutaneous every 6 months. Timing matters. The first denosumab injection should occur within one month of the last romosozumab dose. Dr. Felicia Cosman, professor of medicine at Columbia University, has stated: "There should be no gap between the anabolic phase and the antiresorptive consolidation. A gap of even a few months can erode the BMD gains you worked to achieve."

The transition study embedded in the FRAME trial extension tracked patients who moved from romosozumab to denosumab. At month 36 (24 months after transition), lumbar spine BMD was 14.0% above baseline, and total hip BMD was 7.1% above baseline (Cosman et al., JBMR 2018). These gains were not only maintained but continued to accrue under denosumab, because denosumab suppresses the residual resorption that would otherwise chip away at newly formed bone.

Monitoring after the switch is simple. Obtain a DXA scan 12 months after starting denosumab to confirm BMD stability or gain. Check serum CTX to verify resorption suppression. If BMD is stable or improving, continue denosumab on its 6-month schedule. There is no established maximum duration, though the 10-year FREEDOM extension data support long-term use with ongoing fracture reduction (Bone et al., Lancet Diabetes Endocrinol 2017).

Switching from Denosumab to Romosozumab: The Less-Studied Direction

This switch is more complex, more risky, and far less common. But it does arise clinically.

The primary concern is denosumab discontinuation rebound. When denosumab is stopped, bone turnover markers surge above pre-treatment levels within 3 to 6 months. This rebound resorption causes rapid bone loss and, in some patients, clusters of multiple vertebral fractures. A 2017 analysis published in the Journal of Bone and Mineral Research documented cases of multiple vertebral fractures occurring within 7 to 16 months after denosumab cessation (Cummings et al., JBMR 2018). The risk is highest in patients who had been on denosumab for several years and who had pre-existing vertebral deformities.

Can romosozumab serve as the bridge? Theoretically, its bone-forming action could offset the rebound resorption. But the data are thin. A small study (N=34) by Leder et al. examined switching from denosumab to romosozumab and found that bone formation markers did increase, but resorption markers also rose once denosumab's effect waned. BMD changes were modest and variable (Leder et al., JCEM 2021). The anabolic window was blunted compared with treatment-naive patients.

"Romosozumab after denosumab does not produce the same magnitude of bone formation you see in anabolic-naive patients," noted Dr. Benjamin Leder of Massachusetts General Hospital in the study's discussion. "The skeleton appears to have a diminished response to sclerostin inhibition after prolonged antiresorptive exposure."

If this switch is attempted, most experts recommend that the first romosozumab injection be given on the date the next denosumab injection would have been due (i.e., 6 months after the last denosumab dose), with close CTX monitoring at months 3 and 6 to catch early rebound. After 12 months of romosozumab, the patient must still return to an antiresorptive, typically denosumab again or a bisphosphonate.

Head-to-Head Efficacy: What the Trials Show (and Don't Show)

No published randomized trial directly compares denosumab and romosozumab against each other in a traditional head-to-head design. Comparisons must be drawn across trials, which introduces important limitations.

FREEDOM (denosumab): 7,868 postmenopausal women with T-scores between -2.5 and -4.0. Three years of treatment produced a 68% reduction in vertebral fractures, 40% reduction in hip fractures, and 20% reduction in nonvertebral fractures versus placebo. Lumbar spine BMD increased 9.2% and total hip BMD increased 6.0% at 36 months [2].

ARCH (romosozumab → alendronate vs. alendronate alone): 4,093 postmenopausal women with osteoporosis and a fragility fracture. At month 12, romosozumab increased lumbar spine BMD by 13.7% versus 5.0% with alendronate. After the switch to alendronate in year 2, the romosozumab-first group maintained superiority: 48% lower risk of new vertebral fractures and 38% lower risk of clinical fractures at 24 months [1].

FRAME (romosozumab vs. placebo, then both groups to denosumab): 7,180 postmenopausal women. Romosozumab reduced vertebral fractures by 73% versus placebo at 12 months. After both groups switched to denosumab, the romosozumab group maintained lower fracture rates through 24 months (Cosman et al., NEJM 2016).

Cross-trial BMD comparisons suggest romosozumab builds bone faster. Its 13.7% lumbar spine gain at 12 months dwarfs denosumab's roughly 5-6% gain at the same timepoint. But denosumab's fracture reduction data extend to 10 years, while romosozumab's data are limited to 12 months of exposure followed by an antiresorptive transition.

Safety Differences That Affect Switching Decisions

The cardiovascular signal with romosozumab is the single most important safety distinction.

In ARCH, romosozumab was associated with a higher rate of adjudicated major adverse cardiovascular events (MACE): 2.5% versus 1.9% with alendronate over the first 12 months (Saag et al., NEJM 2017). This prompted the FDA to add a boxed warning contraindicating romosozumab in patients who have had a myocardial infarction or stroke within the preceding year. The European Medicines Agency went further, listing any history of MI or stroke as a contraindication.

Denosumab does not carry a cardiovascular warning. Its primary safety concerns are:

• Discontinuation rebound: rapid bone loss and vertebral fractures if stopped without bridging to bisphosphonate therapy. This is the most clinically significant risk.
• Atypical femoral fractures (AFF): rare, estimated at 0.8 per 10,000 patient-years over 10 years of use (Bone et al., JBMR 2020).
• Osteonecrosis of the jaw (ONJ): very rare in the osteoporosis-dose setting; roughly 5.2 per 100,000 patient-years in the FREEDOM extension.
• Hypocalcemia: more common in patients with renal impairment or vitamin D deficiency. Correct vitamin D levels before starting.

For the patient with cardiovascular risk factors, the choice is clearer: denosumab first, potentially as the only agent. For the patient at very high fracture risk and low cardiovascular risk, romosozumab first followed by denosumab remains the optimal sequence.

Cost and Insurance Considerations

Both drugs are expensive. Neither is available as a generic.

Romosozumab (Evenity) carries a wholesale acquisition cost (WAC) of approximately $1,825 per monthly injection, totaling roughly $21,900 for the full 12-month course. Most commercial insurers require prior authorization and documentation of very high fracture risk (prior fracture plus low T-score). Medicare Part B covers romosozumab as a physician-administered injectable, though cost-sharing can reach 20% of the allowed amount without supplemental coverage.

Denosumab (Prolia) has a WAC of approximately $1,700 per injection, or $3,400 per year. Because it is also physician-administered, Medicare Part B covers it under similar terms. Generic denosumab is not expected in the US until at least 2025, and biosimilar timelines remain uncertain due to ongoing patent litigation.

Patient assistance programs exist for both drugs. Amgen (manufacturer of both Prolia and Evenity) offers copay cards that can reduce out-of-pocket costs to as low as $0 for commercially insured patients. Medicare patients are not eligible for manufacturer copay cards but may qualify for foundation-based assistance through organizations like the HealthWell Foundation or the Patient Advocate Foundation.

The total cost of the romosozumab-to-denosumab sequence over 3 years (12 months romosozumab + 24 months denosumab) is approximately $28,700 at WAC, compared with $10,200 for 3 years of denosumab alone. That cost difference is the trade-off for the additional BMD gains and potentially deeper fracture risk reduction from the anabolic-first approach.

How to Decide: A Practical Clinical Framework

The decision tree for sequencing hinges on three variables: fracture risk severity, cardiovascular status, and prior treatment history.

Patient at very high fracture risk, no cardiovascular contraindication, treatment-naive: Start romosozumab 210 mg monthly for 12 months. Transition to denosumab 60 mg every 6 months. This is the gold-standard sequence per AACE and Endocrine Society guidelines.

Patient at high fracture risk, cardiovascular disease present or recent: Start denosumab 60 mg every 6 months. Romosozumab is contraindicated or requires careful risk-benefit discussion. Do not switch to romosozumab later unless cardiovascular risk has been addressed and the treating cardiologist agrees.

Patient already on long-term denosumab, BMD plateau, no cardiovascular risk: Switching to romosozumab may offer incremental benefit, but expect a blunted anabolic response. If attempted, time the first romosozumab dose at the 6-month mark after the last denosumab injection. Monitor CTX at 3 and 6 months. Return to an antiresorptive after 12 months.

Patient completing romosozumab who cannot tolerate denosumab: Transition to oral alendronate 70 mg weekly or IV zoledronic acid 5 mg annually. The ARCH trial demonstrated the romosozumab-to-alendronate sequence is effective. Zoledronic acid is preferred if adherence to oral bisphosphonates is a concern.

Regardless of sequence, monitor DXA at 12-month intervals, maintain 25-hydroxyvitamin D above 30 ng/mL, and ensure calcium intake of 1,000 to 1 to 200 mg/day from diet and supplements combined (NOF guidelines).